Aspen Neuroscience (ASPE) chair Hasnain acquired 36,349 shares

Insider transactions reported

Faheem Hasnain (Executive Chair at Aspen Neuroscience Inc., ASPE) reported that they acquired 36,349 shares on Nov 2, 2026. After these transactions the filing shows 7,120 shares held indirectly (See Footnote 2.).

Reporting person

Hasnain Faheem

Role

Executive Chair

Options and other derivatives

Holdings before and after

• Common Stock: 0 to 7,120 indirect, See Footnote 2.
• Series A-1 Convertible Preferred Stock: 14,913 to 0 indirect, See Footnote 2.
• Series A-2 Convertible Preferred Stock: 14,316 to 0 indirect, See Footnote 2.
• Series C Convertible Preferred Stock: 7,120 to 0 indirect, See Footnote 2.

Other positions listed

• Common Stock: 26,658 direct

Footnotes from the filing

1. 1. Each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the Preferred Stock ) automatically converted on a 1-for-9.8821 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
2. 2. Securities held by the Hasnain Revocable Trust.

Transaction codes in this filing

Conversion of a derivative:

Code C marks the conversion of a derivative, such as preferred stock or units, into another security.

FAQ